

# IRMS management and organization for the Olympic Games

**Corinne Buisson, Claire Frelat, Magnus Ericsson**

22-23 Sept 2023, Workshop IRMS, London

# Olympic Games: Consequences for the lab



**Consequence 1:** analysis for OG not feasible in the current laboratory: need to move


**Consequence 2:** getting ready for high throughput and efficiency in a short time: need for instrument change and (re)validation

# Olympic Games: Consequences for IRMS analysis


What we had....



IonVantage



lyticOS®  
SOFTWARE SUITE BY ELEMENTAR



What we need for OG...



X 4 and

lyticOS®  
SOFTWARE SUITE BY ELEMENTAR

➔ Need to purchase/rent 2 GC-C-IRMS and 1 IRMS

# Olympic Games: Consequences for IRMS analysis

What we had....



2 x Ultimate 3000 (Dionex !)



System too old: spare parts may be not available in case of problem



1 x Vanquish™ Core



What we need for OG....



4 x Vanquish™ Core



Need to purchase/rent 3 HPLC systems

# Olympic Games: Consequences for IRMS analysis

What we had....



**Gilson XL4**  
**SPE extraction:**  
**4 cartridges at the same time**

What we need for OG....



**2 x Biotage® Extrahera™ HV-5000**  
**SPE extraction:**  
**24 cartridges at the same time**

 Need to purchase 2 SPE systems


# Olympic Games: Consequences for IRMS analysis

What we have....

What we need for OG....



MassHunter



X 2 and MassHunter



ChemStation



➔ Need to upgrade software



# Olympic Games: Consequences for IRMS analysis

- **New laboratory**
  - Moving in March 2023
  - Start of routine operations May 2023
  - Four floors, 2600 m<sup>2</sup>

➔ 1 year and few months before OG



# Moving organization

Moving in March/May 2023: organizing around this important milestone

**What to do before moving** (from 2022 to march 2023):


- Purchase of new IRMS instruments + initial validation in the “old” lab
- Purchase of the new SPE system + method development + initial validation
- Purchase of the new HPLC to be delivered in the new lab

**What to do during the transition period** (from march to may 2023):

- Moving of 1 GC-C-IRMS + new SPE system and delivery of the new HPLC system = validation of sample prep + IRMS analysis in the new lab
- IRMS analysis continuation in the old lab with the current method

**What to do after final moving** (may 2023)

- Validation of the moving of the 2 other IRMS instruments
- preparing the purchase of another new SPE system + 2 new HPLC (to be installed in September!)
- Preparing purchase/rent of the 4th GC-C-IRMS





# Validation strategy: old lab

Validation of new GC-C-IRMS instruments in the "old" lab: **Validation according to TN + risk assessment to evaluate steps required:**

3.0	GC/C/IRMS Analytical Method Validation Requirements	4
3.1.	Selectivity	4
3.2.	Working Range of the Analytical Method	5
3.2.1.	Linearity of the Ion Source	5
3.2.2.	Linearity of the Instrument	6
3.2.3.	Limit of Quantification (LOQ) in Urine	8
3.3.	Measurement Uncertainty (MU)	9
3.4.	Robustness	10
3.4.1.	Robustness of the Sample Preparation Technique (e.g. HPLC) – Isotopic Fractionation	10
3.4.2.	Robustness of the Derivatization (Acetylation) – if applicable	11
3.4.3.	Robustness of the IRMS System	12
3.5.	Carryover	12
3.6.	Integration of Chromatographic Peaks	12
3.7.	Endogenous Interfering Compounds (ERCs)	15
3.8.	Target Compounds	15
3.9.	Reference Population Data and Method's Fitness-for-Purpose	15

✗ Selectivity not necessary: same sample prep + same instrument than initial validated method

✓ Validation of the working range of the method (performances of the instrument, linearity, LOQ)

✓ Measurement uncertainty determination (linear mixing model)

✓ Robustness (only of the IRMS system, done with uc)

# Validation strategy: old lab

Implementation and performances evaluation of new SPE system in the “old” lab:

- ✓ Optimization of the parameters for SPE
- ✓ Recovery – isotopic fractionation evaluation
- ✓ Comparison study with old system

➡ Pre-validation only => Full validation will be done in the new lab

# Validation strategy: new lab

## Validation of IRMS instruments after relocation



<b>4.0</b>	<b>GC/C/IRMS Analysis Requirements</b>	16
4.1.	Control of the IRMS Performance	16
4.1.1.	Instrument Background	16
4.1.2.	Instrument Stability	17
4.1.3.	System Calibration (adjustment of a $\delta^{13}\text{C}$ value to the $\text{CO}_2$ gas)	17
4.2.	Linearity of the Ion Source and the Instrument	18
4.3.	Use of Reference Materials (RMs)	18
4.4.	Quality Control (QC) Samples	18
4.4.1.	Preparation of QC Samples	20
4.4.2.	Negative QC (NQC):	20
4.4.3.	Positive QC (PQC):	20

Repeatability intra and inter day  
Reproducibility of CQs analysis

# Validation strategy: new lab

Validation of new HPLC + new SPE system and GC-C-IRMS after relocation

- ✓ Repeatability intra and inter day (HPLC system)
- ✓ Recovery – isotopic fractionation (full sample prep: SPE and HPLC)
- ✓ Check of Selectivity (GC-MS analysis)
- ✓ Carry over
- ✓ Robustness (CQs repeatability and reproducibility)
- ✓ Accuracy (QCs, RM and CRMs analysis) and uc assessment (control charts)

IQAS performed successfully



# Validation results

Validation of new HPLC system: stability of RT

	Repeatability Intra Day (n=6)				Repeatability Inter Day (n=6)		
	Mean RT (min)	SD RT (min)	RSD (%)		Mean RT (min)	SD RT (min)	RSD (%)
<b>a-Trenbolone (ISTD)</b>	7.807	0.005	0.06%		7.813	0.003	0.04%
<b>11bOH Ac/11KetoE Ac</b>	15.950	0.012	0.08%		15.965	0.010	0.06%
<b>Bold Ac</b>	17.064	0.013	0.08%		17.082	0.011	0.06%
<b>E Ac</b>	19.192	0.015	0.08%		19.210	0.012	0.06%
<b>Testo Ac</b>	21.242	0.017	0.08%		21.263	0.012	0.06%
<b>Bold M1 Ac</b>	25.025	0.018	0.07%		25.049	0.015	0.06%
<b>Etio Ac/A Ac</b>	27.008	0.018	0.07%		27.031	0.016	0.06%
<b>5adiol diAc</b>	39.661	0.014	0.03%		39.673	0.011	0.03%
<b>5bdiol diAc</b>	39.868	0.014	0.04%		39.881	0.011	0.03%
<b>Pdiol diAc</b>	43.479	0.018	0.04%		43.493	0.013	0.03%





# Validation results



Validation of relocated GC-C-IRMS: accuracy (in house prepared RMs (with  $\delta^{13}\text{C}$  values traceable to a CRM))

	<b>-30.08</b>	<b>-31.95</b>	<b>-19.91</b>	<b>-32.11</b>	<b>-33.81</b>	<b>-35.31</b>	<b>-31.96</b>	<b>-16.30</b>	<b>-33.80</b>	<b>-29.67</b>	<b>-22.58</b>	<b>-30.56</b>	<b>-32.29</b>	
	<b>16en Ac</b>	<b>SI</b>	<b>Etio Ac</b>	<b>Andro Ac</b>	<b>5bdiol diAc</b>	<b>5adiol diAc</b>	<b>Bold M1 Ac</b>	<b>11KetoE Ac</b>	<b>EpiT Ac</b>	<b>Testo Ac</b>	<b>Pdiol diAc</b>	<b>Bold Ac</b>	<b>11bOH A Ac</b>	<b>RSQ</b>
<b>M-AN-41</b>	-30.98	-32.00	-20.07	-32.35	-33.93	-35.52	-32.44	-16.32	-34.28	-30.05	-22.09	-30.77	-32.81	0.9988
	-30.70	-32.22	-20.06	-31.98	-33.79	-35.30	-32.37	-16.54	-34.08	-30.03	-22.64	-30.94	-32.09	0.9992
	-30.71	-32.05	-20.20	-32.37	-33.60	-35.66	-32.45	-16.41	-34.12	-30.17	-22.74	-30.93	-32.34	0.9993
	-30.70	-32.05	-20.15	-32.02	-33.49	-35.23	-32.38	-16.49	-34.15	-30.29	-22.52	-31.04	-32.25	0.9987
	-30.57	-32.66	-19.96	-32.20	-33.86	-35.70	-32.41	-16.29	-34.39	-30.05	-22.43	-30.80	-32.21	0.9992
<b>M-AN-97 (B/BM1)</b>	-30.59	-32.41	-20.26	-32.43	-33.59	-35.24	-32.35	-16.29	-34.28	-30.06	-22.91	-31.34	-32.61	0.9990
	-30.77	-32.25	-20.20	-32.69	-33.70	-35.03	-32.51	-16.43	-34.38	-30.20	-22.96	-31.18	-32.72	0.9987
	-30.34	-32.08	-20.03	-32.20	-33.26	-35.06	-32.26	-16.43	-34.03	-29.81	-22.43	-30.71	-32.42	0.9992
	-30.70	-32.43	-19.86	-31.83	-33.69	-35.58	-32.25	-16.22	-33.91	-29.54	-22.64	-30.75	-32.38	0.9991
	-30.81	-32.22	-19.96	-32.52	-33.67	-35.57	-32.33	-16.33	-34.22	-29.87	-22.68	-30.99	-32.69	0.9994
<b>M %o</b>	<b>-30.69</b>	<b>-32.24</b>	<b>-20.08</b>	<b>-32.26</b>	<b>-33.66</b>	<b>-35.39</b>	<b>-32.37</b>	<b>-16.37</b>	<b>-34.18</b>	<b>-30.01</b>	<b>-22.60</b>	<b>-30.94</b>	<b>-32.45</b>	
<b>SD %o</b>	<b>0.17</b>	<b>0.21</b>	<b>0.13</b>	<b>0.27</b>	<b>0.19</b>	<b>0.25</b>	<b>0.08</b>	<b>0.10</b>	<b>0.15</b>	<b>0.22</b>	<b>0.25</b>	<b>0.20</b>	<b>0.24</b>	
<b>CV %</b>	<b>0.5%</b>	<b>0.7%</b>	<b>0.6%</b>	<b>0.8%</b>	<b>0.6%</b>	<b>0.7%</b>	<b>0.3%</b>	<b>0.6%</b>	<b>0.4%</b>	<b>0.7%</b>	<b>1.1%</b>	<b>0.7%</b>	<b>0.7%</b>	
<b>Ecart</b>	<b>0.61</b>	<b>0.29</b>	<b>0.17</b>	<b>0.15</b>	<b>-0.15</b>	<b>0.08</b>	<b>0.41</b>	<b>0.07</b>	<b>0.38</b>	<b>0.34</b>	<b>0.02</b>	<b>0.38</b>	<b>0.16</b>	

# Validation results

Validation of new HPLC + new SPE system and GC-C-IRMS after relocation

Experimental design for robustness

QC 1 old_SPE	QC 2 old_SPE	QC 1 Extra 05	QC 2 Extra 05	QC 3 Extra 05	QC 4 Extra 05
HPLC 9	HPLC 8	HPLC 9	HPLC 9	HPLC 9	HPLC 8
Isop 7	Isop 5	Isop 7	Isop 7	Isop 7	Isop 5

Results

Old lab

QCN	Etio	Andro	11KétoE	11bOH Andro	E	Testo	5b Adiol	5a Adiol	Pdiol
<b>Control Chart mean value</b>	-22.46	-21.91	-21.61	-21.80	-22.88	-22.48	-22.80	-22.77	-22.08
<b>uc (initial validation)</b>	0.5	0.4	0.3	0.6	0.7	0.7	0.6	0.7	0.7
<b>QCN 1 old_SPE Isop 7</b>	-22.57	-22.19	-20.17	-22.09	-23.84	-22.96	-23.52	-23.42	-20.95
<b>QCN 2 old_SPE Isop 5</b>	-22.30	-21.93	-21.61	-21.64	-22.56	-21.52	-22.19	-22.45	-21.96
<b>QCN 1 Extra05 Isop 7</b>	-22.23	-21.61	-21.32	-21.91	-23.44	-22.84	-22.73	-22.87	-21.99
<b>QCN 2 Extra05 Isop 7</b>	-22.14	-22.00	-21.22	-22.25	-23.00	-22.58	-22.67	-22.51	-20.71
<b>QCN 3 Extra05 Isop 7</b>	-21.90	-21.78	-20.97	-22.16	-22.19	-22.68	-22.91	-22.70	-20.72
<b>QCN 4 Extra05 Isop 5</b>	-22.40	-21.73	-21.32	-21.55	-22.35	-21.80	-22.12	-22.14	-21.85
<b>Mean Old_SPE</b>	-22.43	-22.06	-20.89	-21.86	-23.20	-22.24	-22.86	-22.93	-21.46
<b>SD Old_SPE</b>	0.19	0.19	1.02	0.32	0.91	1.02	0.94	0.69	0.72
<b>Mean Extra 05</b>	-22.17	-21.78	-21.21	-21.97	-22.75	-22.48	-22.61	-22.56	-21.32
<b>SD Extra 05</b>	0.21	0.16	0.16	0.31	0.58	0.46	0.34	0.31	0.70
<b>Diff (Old_SPE – Extra 05)</b>	<b>-0.26</b>	<b>-0.28</b>	<b>0.31</b>	<b>0.10</b>	<b>-0.45</b>	<b>0.24</b>	<b>-0.25</b>	<b>-0.37</b>	<b>-0.14</b>



# Olympic Games Prerequisites

- Number of samples

	OG	ParaOG
• Urine IC	3099	1200
• Urine OOC	1551	800
• Serum	577	300
• Whole blood	578	300
• DBS	200	100

- Hub model

- Samples to be collected and gathered in a “sample hub” organized by Paris2024
- One major delivery from the hub to the laboratory per day
- Late coming samples are welcomed in a narrow time window after the large delivery, a few hours.

- Reporting time

- 36-48 h
- ESA 72h
- IRMS 72H

# Olympic Games preparations

- Staff and shifts

	Total staff	Comment
Sample reception, aliquotage	30	Lab staff and students,
EPO	10	lab staff and experts
IRMS prep	4	Lab staff, experts (and students)
IRMS analysis and LC-UV prep	6	Lab staff and experts
PIIINP, hCG, Sysmex, pH/SG, hGH, Transfusion	8	lab staff students and experts
Gene doping	2	Lab staff and experts
hGH isoforms	4	Lab staff and experts
LC-HRMS prep	5	Lab staff, experts and students
LC-HRMS peptide prep	5	Lab staff, experts and students
GC-MS/MS prep	5	Lab staff, experts and students
Large peptides prep	2	Lab staff, experts and students
DBS prep	2	Lab staff, experts and students
IGF-1 prep	2	Lab staff, experts and students
Steroids in blood prep	2	Lab staff, experts and students
LC-HRMS instrument and evaluation	10	Lab staff and experts
LC-HRMS peptide instrument and evaluation	10	Lab staff and experts
GC-MS/MS instrument and evaluation	10	Lab staff and experts
Large peptides instrument and evaluation	4	Lab staff and experts
DBS instrument and evaluation	2	Lab staff and experts
IGF-1 instrument and evaluation	2	Lab staff and experts
Confirmation MS	3	Lab staff
Steroids in blood instrument and evaluation	2	Lab staff and experts
Reporting negative	2	Lab staff
Reporting positive samples	1	Director + director panel
Director panel	4	Lab directors
	<b>137</b>	

Shift Reception	04h00-10h00
Shift preparation MS	08h00-16h00
Shift 1 analysis Chemistry	8h00-17h00
Shift 2 analysis Chemistry	16h00-01h00
Shift 1 analysis bio	8h-17h00
Shift 1 EPO	7h-15h00
Shift 2 EPO	12h30-20h30
Shift 1 IRMS	7h-15h00
Shift 1 IRMS	12h30-20h30
Shift 1 Conf MS	8h00-17h00
Shift 1 Conf MS	16h00-01h00
Shift Guard for instruments	24h00-8h00

## Need help for :

IRMS prep (SPE/hydrolyse/LLE)  
and/or HPLC prep and Elementar  
instrument (lyticOS)



# Olympic Games organization: conclusion

## What is ready today

- ✓ New lab = lab for OG validated!
- ✓ 3 GC-C-IRMS for T, B and metabolites validated
- ✓ 1 GC-C-IRMS validated for 19NA and Formestane
- ✓ 1 SPE system validated
- ✓ 2 HPLC systems validated

<b>Analyte</b>	<b>LOQ (ng/mL)</b>	<b><math>u_{c\_Max}</math> (<math>\delta</math>) (‰)</b>
<b>ERCs</b>	50	0.7
<b>T, 5<math>\alpha</math>Adiol</b>	10	0.7
<b>5<math>\beta</math>Adiol</b>	20	0.7
<b>EpiA</b>	20	1.0
<b>E, F</b>	50	1.0
<b>A, Etio</b>	100	0.7
<b>B / BM1</b>	2.5	1.0
<b>6<math>\alpha</math>-OH-AD</b>	10	1.0



# Olympic Games organization: conclusion

## What remains to be done ...

- ➔ Order and validate the fourth (and last!) IRMS system (installation planned early 2024)
- ➔ Installation and Validation the 2 new HPLC systems (before end of 2023)
- ➔ Installation and Validation the new SPE system (before end of 2023)
- ➔ Train a new technician from the lab (in progress ...)
- ➔ Upgrade of GC-MS software and validation of its use
- ➔ Validation of 6aOH-AD (end of 2023 – beginning of 2024)
- ➔ Recruiting for OG! (invitation soon ...)
- ➔ Pass the WADA audit(s)





**Merci!**